Experience

Davis Polk is advising McKesson Corporation on its acquisition of Medical Specialties Distributors, LLC from New Mountain Capital. The transaction is valued at $800 million, and is subject…

Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…

Davis Polk is advising Roche on its $1.9 billion acquisition of Flatiron Health, Inc. The transaction, which is expected to close in the first half of 2018, is subject to customary closing…

Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…

Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the…

Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition, InflaRx has granted the underwriters a 30-day option to purchase…

Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health…

Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross…

Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…

Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total…